BRIDGEWATER, N.J. — Savient Pharmaceuticals has appointed a new finance chief.
John Hamill will serve as Savient's SVP and CFO, where he will be responsible for all financial and accounting functions of the company. Hamill, who brings more 25 years of global financial and administrative operational experience to his new role, will directly report to Savient president and CEO Lou Ferrari. Prior to joining the drug maker, Hamill served as CFO of PharmaNet Development Group, a leading global supplier of drug development services.
"John has a valuable combination of global financial, operational and public company experience which will be vital for us as we continue to execute on our strategic initiatives to drive growth opportunities for Krystexxa both in the U.S. and in markets around the world," Ferrari said. "He will be responsible for all aspects of our financial functions and for ensuring the company meets its growth objectives in the most cost-effective manner through the implementation of financial and operational controls and the execution of the financial roadmap."